Kornimate/medical-research-clean huggingface dataset:
impact of a previous cs on the ongoing pregnancy rate in single euploid frozen embryo transfer (et)

Conditions: Infertility; Implantation

Summary: as embryo ploidy is a crucial factor not only for implantation but also for maintenance of a pregnancy, the aim of this study is to evaluate the impact of the cs / isthmocele on the ongoing pregnancy rates and the implantation site in single euploid frozen embryo transfer, independent of the endometrial preparation approach.

the impact of a previous cs on the future fertility in the general population is discussed controversially, but it seems that the clinical and social circumstances leading to the cs have a greater effect on future fertility than the surgical procedure itself (gurol-urganci et al., 2013, 2014; evers et al., 2014). however, this might be different in women who do not conceive spontaneously after a previous cs and need to undergo art due to secondary infertility. whereas some studies describe a reduction of implantation, ongoing pregnancy, and live birth (lb) rates (vissers et al., 2020; wang et al., 2020; diao et al., 2021; friedenthal et al., 2021; van den tweel et al., 2022), others describe a negative impact of a previous cs only in the presence of an isthmocele (diao et al., 2021) or no impact (patounakis et al., 2016). a case control study evaluated whether there are any differences in the location and distance to the internal cervical ostium of the implantation site of the intrauterine gestation sacs, early pregnancy symptoms and pregnancy outcome at 12 weeks gestation between women with and without a previous caesarean section (cs) in patients who conceived naturally (naji et al., 2013). investigators concluded that the presence of a cs scar affects the site of implantation, and also that the distance between implantation site and the scar is related to the risk of spontaneous abortion. this is a purely observational study without any intervention. participants will be stratified into different groups according to their previous obstetrical history. total sample size will include 1050 participants undergoing a frozen embryo transfer (fet) cycle. isthmocele will be defined according to de vaate et al (bij de vaate et al., 2011) as: visible anechogenic area of at least 1 mm depth at the site of the cesarean scar.

Eligibility criteria:
inclusion criteria: - all participants undergoing a single euploid fet, independent of the endometrial preparation approach exclusion criteria: * intracavitary fluid during preparation for fet * known anomaly of the uterus or the adnexae (e.g.: fibroids, polyps, hydrosalpinx, endometriosis, adenomyosis) * embryo which was biopsied on day 7 * poor quality embryo which was transferred (gardner criteria: ac / bc / cb, biopsied on day 6 and cc embryos from both, day 5 and day 6 biopsies, classified as "poor" quality embryos) * history of recurrent abortion * antiphospholipid syndrome / autoimmune diseases

Keywords: implantation infertility isthmocele cesarean section
an observational study in patients using novomix® 30 or levemir® for treatment of type 1 or type 2 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to investigate efficacy and safety of novomix® 30 (biphasic insulin aspart 30) or levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * macedonian people with diabetes mellitus (type 1 or type 2)
safety and efficacy of switching to a fdc of b/f/taf from e/c/f/taf, e/c/f/tdf, or atv+rtv+ftc/tdf in virologically suppressed hiv-1 infected women

Conditions: HIV-1 Infection

Summary: the primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (fdc) of bictegravir/emtricitabine/tenofovir alafenamide (b/f/taf) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (e/c/f/taf), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (e/c/f/tdf), or atazanavir (atv) + ritonavir (rtv) + emtricitabine/tenofovir disoproxil fumarate (ftc/tdf) in virologically suppressed hiv-1 infected women.


Eligibility criteria:
key inclusion criteria medically stable hiv-1 infected women who meet the following criteria: * completion of the week 48 open-label extension (ole) visit or any post week 48 ole visits in gilead-sponsored study gs-us-236-0128, or completion of the week 96 visit or any post week 96 visits in gilead-sponsored study gs-us-292-0109 or completion of the week 144 visit or any post week 144 visits in gilead sponsored studies gs-us-292-0104 or gs-us-292-0111. * currently on a stable antiretroviral regimen consisting of e/c/f/taf, e/c/f/tdf, or atv+rtv+ftc/tdf continuously for ≥ 12 consecutive weeks preceding the screening visit * documented plasma hiv-1 rna levels \< 50 copies/ml for ≥ 12 weeks preceding the screening visit. after reaching hiv-1 rna \< 50 copies/ml, single values of hiv-1 rna ≥ 50 copies/ml followed by re-suppression to \< 50 copies/ml is allowed * hiv-1 rna \<50 copies/ml at screening * estimated glomerular filtration rate (egfr) ≥ 50 ml/min (≥ 0.83 ml/sec) according to the cockcroft-gault formula at the screening visit note: other protocol defined inclusion/exclusion criteria may apply.
a double-blinded, randomised, two -period crossover euglycemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of biochaperone insulin lispro and insulin lispro (humalog®) in subjects with type 1 diabetes

Conditions: Diabetes Mellitus Type 1

Summary: the addition of biochaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to a facilitation of the absorption of the insulin after subcutaneous injection. the aim of the trial is to assess the efficacy and safety of biochaperone insulin lispro in subjects with type 1 diabetes under a dose of 0.2 u/kg. this trial is a single-center, randomised, double-blinded, two-treatment, two-period cross-over, 6-hour euglycaemic glucose clamp trial in subjects with type 1 diabetes mellitus. each subject will be randomly allocated to a single dose of biochaperone insulin lispro 0.2 u/kg and a single dose of humalog® 0.2 u/kg on 2 separate dosing visits.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for at least 12 months. * treated with multiple daily insulin injections or insulin pump for at least 12 months. * body mass index (bmi): 18.0-28.0 kg/m². exclusion criteria: * type 2 diabetes mellitus. * receipt of any investigational product within 3 months prior to first dosing. * clinically significant abnormalities as judged by the investigator. * any systemic treatment with drugs known to interfere with glucose metabolism. * history of alcoholism, or drug/chemical abuse as per investigator's judgement. * use of tobacco or nicotine-contained product within 5 years prior to screening. * blood or plasma donation in the past month or more than 500 ml within 3 months prior to screening.
l-arginine metabolism in essential hypertension

Conditions: Essential Hypertension

Summary: essential hypertension is characterized by impaired endothelial function. data derived from normotensive subjects with a genetic predisposition to arterial hypertension suggest that endothelial dysfunction is a cause rather than a consequence of the condition. given that, in normotensive offspring of hypertensive parents, impaired endothelium dependent vasodilation can be restored by supplementation of the nitric oxide (no) precursor l-arginine, a defect in the l-arginine/no pathway can be postulated. the investigators at the university of erlangen-nuremberg, hypothesize that impaired endothelial function in essential hypertension is associated with alterations in l-arginine metabolism and transport. this study will determine whether metabolism and transport of l-arginine are altered in patients with essential hypertension and whether these potential alterations can be targeted therapeutically.


Eligibility criteria:
inclusion criteria: * males, ages 18-65 * male and female healthy control subjects ages 18-65 exclusion criteria: * any other coexisting condition * advanced damage of vital organs (grade iii und iv retinopathy) * therapy with a not approved concomitant medication in the last 4 weeks prior to intake of the first trial medication, especially lipid lowering and antidiabetic medications (washout phase) * blood donation within the last 4 weeks * patients with arterial fibrillation or atrioventricular (av)-block (ii and more) * patients with anamnestic myocardial infarct * patients with depression * patients with seizure disorders * patients with unstable angina pectoris including electrocardiogram (ecg)-aberrations or cardiac insufficiency new york heart association (nyha) stadium iii and iv * history of a malignant illness with the exception of those patients who have recovered for more than 10 years or have a basalioma of the skin. * actual or anamnestic alcohol or drug abuse * history of organ transplant * anaphylaxis or known therapy resistance to any of the used test matters. * therapy with a not approved concomitant therapy * participation in another study within three months prior to study inclusion * illnesses, which can influence the pharmacodynamics or pharmacokinetics of the test substance * liver or kidney diseases: sgot, gpt , γ-gt, ap, bilirubin and creatinine above 200% of standard * patients who are not sufficiently compliant; or patients who are not capable or willing to appear for controlling visits. * severe or unstable medical or psychiatric illnesses, which will, in the estimation of the examiner, endanger the safety of the proband or the successful participation in the study * presumed risk of transmission of hiv or hepatitis via blood from the proband

Keywords: essential hypertension
egyptian arthroplasty surgeons' antibiotics usage awareness

Conditions: Infections Joint Prosthetic

Summary: total hip arthroplasty (tha) and total knee arthroplasty (tka) are procedures successfully applied to manage various end-stage chronic hip and knee diseases, such as osteoarthritis, rheumatoid arthritis, and femoral head avascular necrosis, as well as acute conditions, such as the neck of femur fractures, with excellent long-term functional outcomes. one of the devastating complications after such a procedure is periprosthetic joint infection (pji). various precautions are proposed to guard against such complications; one is the administration of perioperative antibiotics. however, injudicious or misuse of antibiotics could lead to the emergence of antimicrobial resistance, further complicating this matter. this is why various scientific and research organizations have proposed guidelines and a consensus for proper antibiotic use in perioperative tha and tka surgery. antibiotic prophylaxis during primary tha and tka can reduce the risk of pji and surgical site infections. however, there is a lack of consensus on the optimal dosages and duration of prophylaxis, and guidelines vary among institutions. alternatives such as extended oral antibiotic prophylaxis and different antibiotic regimens are being explored. international research is needed to establish best practices and determine the potential risks of antibiotic prophylaxis during primary tha and tka. unfortunately, the investigators are unaware of such guidelines proposed by any egyptian health authority to guide and control the proper utilization of antibiotics during orthoapedic practice in general and joint replacement surgeries (tha and tka) in particular.

this study will be an online-based questionnaire investigating surgeons' perspectives on antibiotics utilization during primary total hip and knee arthroplasty surgeries and investigate their thoughts about the necessity for developing local guidelines.

Eligibility criteria:
inclusion criteria: all egyptian registered members of the egyptian pelvis and hip society, practicing egyptian joint replacement surgeons (performing surgeries as a leading surgeon) who are willing to participate exclusion criteria: * members not listed in the e-mail directory of the society * surgeons refusing to participate * young surgeons who are not practicing independently
effect of tablet-based games on executive functions in older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the primary objective of this study is to investigate whether a tablet-based role-playing game is more effective than tablet-based word or image puzzles at improving executive functions in older adults with mild cognitive impairment. the secondary objective of this study is to investigate whether a tablet-based role-playing game will show higher levels of engagement (measured by time played) in older adults with mild cognitive impairment than tablet-based word or image puzzles.

the purpose of this study is to examine the use of tablet-based (ipad or android) video games as a means of improving executive functions in older adults with mild cognitive impairment (petersen, smith, waring, et al., 1999). the worldwide rising average age of the population and increasing incidence of dementia has created an urgent need for the development of effective and engaging therapies to mitigate age- and dementia-related cognitive decline. much evidence supports the use of cognitive therapies as a means of improving general cognition in older adults. video games may offer benefits over traditional cognitive therapies as they are challenging and fun, provide frequent feedback which motivates and encourages user engagement, and are widely available at low cost on tablet devices. this study will be implemented as a single blinded randomized control trial structured as a 2 x 2 mixed design with one repeated factor (time: pre-training, post-training) and one between-subject factor (group: treatment, active control). forty-two older adults with mild cognitive impairment will be randomly assigned to play either a role-playing game, or a selection of word or image puzzles, for 5 or more hours a week for a period of 8 weeks. participants can have a study partner assist them in the study. a study partner can help the participant with using the tablet and navigating menu in the game, but cannot play the game along with the participant. participants will be assessed pre and post training with the cambridge brain sciences (www.cambridgebrainsciences.com) online battery of 12 cognitive tasks. these tasks are "based on well-established paradigms from the cognitive neuroscience literature, to measure planning, reasoning, attention, and working memory abilities" (hampshire, highfield, parkin, et al., 2012, p. 1236).

Eligibility criteria:
inclusion criteria: * 60 years of age or older * fluent in english * diagnosis of mild cognitive impairment * normal or corrected hearing and vision * can operate the touch screen on an ipad * access to a tablet (ipad or android) for 8 weeks of the study exclusion criteria: * have started taking memory medication in the last 3 months * have experience in any of the tablet-based games included in the study

Keywords: video games, tablet
odense androgen study - the effect of testim and training in hypogonadal men

Conditions: Hypogonadism; Metabolic Syndrome

Summary: the purpose of this study is to determine the effect of training and testim on hypogonadism.

the effect of testim and training in hypogonadal men.

Eligibility criteria:
inclusion criteria: * male 65-78 * bioavailable testosterone \< 7.3 nmol/l * waist \> 94 cm exclusion criteria: * haematocrit \> 0.50 * known c. prostate or psa \> 3 myg/l * known malignant disease * alcohol or drug abuse * bmi \> 40 kg/m2 * use of 5 alpha reductance inhibitors * plan to father children

Keywords: body composition physical activity metabolic syndrome
family-based genetic long-term study of brain function in schizophrenia

Conditions: Schizophrenia; Blooddraw; MRI

Summary: the goal of this research is to find out possible susceptible gene(s) in schizophrenic patients with family history and 5-year period functional changes of brain among the members of family, in order to further analysis factors and their interactions.

schizophrenia is a serious mental disease, highly family inheritable inclination. by means of traditional psychiatry diagnosis, genetics and long term brain change researches will help to unveil the secret of schizophrenia and other factors. the advantage of comparative gene hybridization is that chromosome copy number alterations can be detected; this technique has been widely applied in many researches, such as cancer, mental retardation screening and autism. as we known, we are the first one use this technique in chromosome abnormality research for family history schizophrenic patient, this study also is the first one to track the relationship of long term brain function alteration and chromosome abnormality in taiwan.

Eligibility criteria:
inclusion criteria: 1.psychiatry doctor diagnosed who met the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for schizophrenia or schizoaffective disorder, family history, age older than 15 will be recruited for participation in this study. participants agree and sign informed consent forms will eligible to participate this experiment. 2.10-20c.c blood will be drawn from the participants. 3.participants need to understand procedures and assays of this experiment. 4.at least one psychiatry doctor interview needed, participants and their family voluntarily join this interview, approximately 30-45min. exclusion criteria: 1. participant can not understand procedures and assays of this experiment. 2. participant has another major mental disease other than the inclusion criteria. 3. participant has material abuse history, it could seriously influence diagnosis. 4. participant has combination diseases, it could seriously influence diagnosis. 5. psychopathy or psychosis can not be categorized in defined group. other considerations: 1. participants, age fewer than 20 needs to their deputy guardians (parents) and their own consent altogether. 2. participants who are inability needs to their deputy guardians (parents) and their own consent altogether.

Keywords: schizophrenia dna mri
deep brain stimulation for alzheimer's disease

Conditions: Alzheimer Disease; Dementia, Alzheimer Type; Deep Brain Stimulation

Summary: background: deep brain stimulation (dbs) is used to modulate the activity of dysfunctional brain circuits. the safety and preliminary efficacy of nucleus basalis of meynert (nbm)-dbs in alzheimer's disease (ad) is proved in a recent phase 1 clinical trial, yet, the mechanism still unknown. objective: 1. to compare the brain structure and functional circuits between a) ad patients with optimal drug treatment (odt) plus nbm-dbs, b) ad with odt and c) normal age-and sex-matched control. 2. to evaluate the clinical effectiveness of nbm-dbs in ad patients 60-75 year-old. 3. to evaluate the abnormal functional circuitry response to acute and chronic nbm-dbs in ad. methods: a total of 30 subjects (10 subjects of ad with odt plus nbm-dbs; 10 subjects of ad with odt and 10 subjects of normal age-and sex-matched subjects) will be enrolled in this prospective, with normal control, phase ii study. study tools will include clinical rating batteries, structure and functional imaging of magnetic resonance (mr) and positron emission tomography (pet), and electroencephalogram (eeg). expected results: nbm-dbs will be proved to be an safe and effective treatment modality in ad patients 60-75 year-old. through multi-modal images and eeg analysis, the possible action mechanisms of nbm-dbs on memory circuit will be discussed. the study results may shed a light on this helpless neurodegenerative disease of dementia.


Eligibility criteria:
inclusion criteria: for groups (ad with/ without dbs) 1. confirmed alzheimer's dementia diagnosis 2. regular medications taking for at least 3 months 3. clinical dementia rating: 0.5 - 2 4. mini mental status examination: ≦ 26 5. amyloid pet: positive 6. informed consent signed by patients or families for normal control group 1. no cognitive impairment (mini mental status examination) 2. amyloid pet: negative 3. informed consent signed by patients and families exclusion criteria: for groups (ad with/ without dbs) 1. structural lesions identified by magnetic resonance imaging (ex: stroke, brain surgery) 2. other neurodegenerative/ neuropsychiatric diseases 3. systemic medical diseases with cognitive impairment (ex: anemia, thyroid disease) 4. can't have regular follow-up visit for normal control group 1. structural lesions identified by magnetic resonance imaging (ex: stroke, brain surgery) 2. dementia/ neurodegenerative/ neuropsychiatric diseases 3. systemic medical diseases with cognitive impairment (ex: anemia, thyroid disease) 4. can't have regular follow-up visit

Keywords: magnetic resonance image
bone marrow cells in myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: this study is aimed to assess the effect of bone marrow cells on arrhythmia risk variables in patients with a acute myocardial infarction.

this is a randomized, double-blinded study, where patients treated with thrombolytic therapy for acute myocardial infarction are randomized to receive bone-marrow derived stem cells or sham-infusion at the time percutaneous coronary intervention of the target vessel. the end-points are many arrhythmia risk variables, suchs as heart rate variability, t-wave alternans and many ecg variables as well as systolic and diastolic left ventricular function.

Eligibility criteria:
inclusion criteria: * acute st-elevation myocardial infarction treated with thrombolytic therapy exclusion criteria: * indication for rescue pci, severe clinical heart failure, age \<18 years

Keywords: stem cell acute myocardial infarction